Gut Microbiota As Emerging Players in the Development of Alcohol-Related Liver Disease

Overview

Journal Biomedicines

Date 2025 Jan 25

PMID 39857657

Authors

Wei Li

Wenkang Gao

Shengqi Yan

Ling Yang

Qingjing Zhu

Huikuan Chu

Affiliations

Soon will be listed here.

Abstract

The global incidence and mortality rates of alcohol-related liver disease are on the rise, reflecting a growing health concern worldwide. Alcohol-related liver disease develops due to a complex interplay of multiple reasons, including oxidative stress generated during the metabolism of ethanol, immune response activated by immunogenic substances, and subsequent inflammatory processes. Recent research highlights the gut microbiota's significant role in the progression of alcohol-related liver disease. In patients with alcohol-related liver disease, the relative abundance of pathogenic bacteria, including , increases and is positively correlated with the level of severity exhibited by alcohol-related liver disease. Supplement probiotics like , as well as , have been found to alleviate alcohol-related liver disease. The gut microbiota is speculated to trigger specific signaling pathways, influence metabolite profiles, and modulate immune responses in the gut and liver. This research aimed to investigate the role of gut microorganisms in the onset and advancement of alcohol-related liver disease, as well as to uncover the underlying mechanisms by which the gut microbiota may contribute to its development. This review outlines current treatments for reversing gut dysbiosis, including probiotics, fecal microbiota transplantation, and targeted phage therapy. Particularly, targeted therapy will be a vital aspect of future alcohol-related liver disease treatment. It is to be hoped that this article will prove beneficial for the treatment of alcohol-related liver disease.

References

Inokuchi S, Tsukamoto H, Park E, Liu Z, Brenner D, Seki E . Toll-like receptor 4 mediates alcohol-induced steatohepatitis through bone marrow-derived and endogenous liver cells in mice. Alcohol Clin Exp Res. 2011; 35(8):1509-18. PMC: 3131439. DOI: 10.1111/j.1530-0277.2011.01487.x. View

Kendrick S, OBoyle G, Mann J, Zeybel M, Palmer J, Jones D . Acetate, the key modulator of inflammatory responses in acute alcoholic hepatitis. Hepatology. 2010; 51(6):1988-97. DOI: 10.1002/hep.23572. View

Li M, Van Esch B, Wagenaar G, Garssen J, Folkerts G, Henricks P . Pro- and anti-inflammatory effects of short chain fatty acids on immune and endothelial cells. Eur J Pharmacol. 2018; 831:52-59. DOI: 10.1016/j.ejphar.2018.05.003. View

Yang W, Yu T, Huang X, Bilotta A, Xu L, Lu Y . Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity. Nat Commun. 2020; 11(1):4457. PMC: 7478978. DOI: 10.1038/s41467-020-18262-6. View

Dubinkina V, Tyakht A, Odintsova V, Yarygin K, Kovarsky B, Pavlenko A . Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease. Microbiome. 2017; 5(1):141. PMC: 5645934. DOI: 10.1186/s40168-017-0359-2. View

Brandl K, Hartmann P, Jih L, Pizzo D, Argemi J, Ventura-Cots M . Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. J Hepatol. 2018; 69(2):396-405. PMC: 6054564. DOI: 10.1016/j.jhep.2018.03.031. View

Cresci G, Bush K, Nagy L . Tributyrin supplementation protects mice from acute ethanol-induced gut injury. Alcohol Clin Exp Res. 2014; 38(6):1489-501. PMC: 4185400. DOI: 10.1111/acer.12428. View

Bajaj J, Kakiyama G, Savidge T, Takei H, Kassam Z, Fagan A . Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant. Hepatology. 2018; 68(4):1549-1558. DOI: 10.1002/hep.30037. View

Park J, Lee S . Fermentative production of branched chain amino acids: a focus on metabolic engineering. Appl Microbiol Biotechnol. 2009; 85(3):491-506. DOI: 10.1007/s00253-009-2307-y. View

10.

Mencin A, Kluwe J, Schwabe R . Toll-like receptors as targets in chronic liver diseases. Gut. 2009; 58(5):704-20. PMC: 2791673. DOI: 10.1136/gut.2008.156307. View

11.

Grander C, Adolph T, Wieser V, Lowe P, Wrzosek L, Gyongyosi B . Recovery of ethanol-induced depletion ameliorates alcoholic liver disease. Gut. 2017; 67(5):891-901. DOI: 10.1136/gutjnl-2016-313432. View

12.

Xie G, Zhong W, Zheng X, Li Q, Qiu Y, Li H . Chronic ethanol consumption alters mammalian gastrointestinal content metabolites. J Proteome Res. 2013; 12(7):3297-306. PMC: 5672944. DOI: 10.1021/pr400362z. View

13.

Sharma A, Roy A, Premkumar M, Verma N, Duseja A, Taneja S . Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial. Hepatol Int. 2022; 16(2):433-446. DOI: 10.1007/s12072-022-10312-z. View

14.

Tan J, McKenzie C, Potamitis M, Thorburn A, Mackay C, Macia L . The role of short-chain fatty acids in health and disease. Adv Immunol. 2014; 121:91-119. DOI: 10.1016/B978-0-12-800100-4.00003-9. View

15.

. Structure, function and diversity of the healthy human microbiome. Nature. 2012; 486(7402):207-14. PMC: 3564958. DOI: 10.1038/nature11234. View

16.

Pan L, Ren Z, Yang J, Li B, Huang Y, Song D . Gut microbiota controls the development of chronic pancreatitis: A critical role of short-chain fatty acids-producing Gram-positive bacteria. Acta Pharm Sin B. 2023; 13(10):4202-4216. PMC: 10547962. DOI: 10.1016/j.apsb.2023.08.002. View

17.

Inagaki T, Moschetta A, Lee Y, Peng L, Zhao G, Downes M . Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006; 103(10):3920-5. PMC: 1450165. DOI: 10.1073/pnas.0509592103. View

18.

Roychowdhury S, Glueck B, Han Y, Mohammad M, Cresci G . A Designer Synbiotic Attenuates Chronic-Binge Ethanol-Induced Gut-Liver Injury in Mice. Nutrients. 2019; 11(1). PMC: 6357124. DOI: 10.3390/nu11010097. View

19.

Leitner U, Brits A, Xu D, Patil S, Sun J . Efficacy of probiotics on improvement of health outcomes in cirrhotic liver disease patients: A systematic review and meta-analysis of randomised controlled trials. Eur J Pharmacol. 2024; 981:176874. DOI: 10.1016/j.ejphar.2024.176874. View

20.

Kim A, McCullough R, Poulsen K, Sanz-Garcia C, Sheehan M, Stavitsky A . Hepatic Immune System: Adaptations to Alcohol. Handb Exp Pharmacol. 2018; 248:347-367. DOI: 10.1007/164_2017_88. View